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Resistant hypertension is deﬁned as uncontrolled blood pressure despite the use of three antihypertensive drugs, including a
diuretic, inoptimaldoses.Treatment resistancecanbeattributed topooradherence toantihypertensive drugs, excessive saltintake,
physician inertia, inappropriate or inadequate medication, and secondary hypertension. Drug-induced hypertension, obstructive
sleep apnoea, primary aldosteronism, and chronic kidney disease represent the most common secondary causes of resistant
hypertension. Severaldrugs caninduce orexacerbate pre-existing hypertension, withnon-steroidalanti-inﬂammatorydrugs being
the most common due to their wide use. Obstructive sleep apnoea and primary aldosteronism are frequently encountered in
patients with resistant hypertension and require expert management. Hypertension is commonly found in patients with chronic
kidney diseaseandis frequently resistantto treatment, while the managementofrenovascular hypertension remains controversial.
A step-by-step approach of patients with resistant hypertension is proposed at the end of this review paper.
1.Introduction
Hypertension represents a major public health problem
aﬀecting more than one billion individuals worldwide [1].
The advent of antihypertensive therapy has substantially
reduced the occurrence of cardiovascular events. However,
antihypertensive therapy failed to achieve blood pressure
control in all patients, with hypertension control rates
remaining in general disappointingly low. Blood pressure
goals are not attained in some patients despite the simulta-
neous use of several antihypertensive medications. Several
terms have been used to deﬁne this condition: “refractory
hypertension”, “diﬃcult-to-treat hypertension”, “diﬃcult-to-
control hypertension”; however, the term “resistant hyper-
tension” seems to prevail.
Resistant hypertension is currently deﬁned as uncon-
trolled blood pressure despite the use of optimal doses of
threeantihypertensive medications,ofwhich oneisadiuretic
[2]. Several factors have been identiﬁed as contributors to
resistant hypertension. Poor patient adherence, physician
inertia, inadequate doses or inappropriate combinations of
antihypertensive drugs, excess alcohol intake, and volume
overload are some of the most common causes of resistance
[2–10]. Secondary forms of hypertension represent another
very important contributor to drugresistance. The list of
secondary forms of hypertension is long and covers a large
variety of conditions(Table 1). Most of these conditions may
result in resistance to pharmacologic therapy of hyperten-
sion.
The management of patients with resistant hyperten-
sion requires a gratifying combination of clinical acumen
and common sense. An extensive workup of all patients
with uncontrolled hypertension is scientiﬁcally unsound,
is very costly and requires immense human and technical
resources. Therefore, practicing physicians need to imple-
ment evidence-based medicine. The eﬀective management
of patients with resistant hypertension requires an appro-
priate combination of physiology and pharmacology, taking
into account the unique characteristics of each case in
order to tailor the therapeutic approach to the individual
patient.
This paper will address the most common secondary
causes of resistant hypertension (drug-induced, obstructive
sleep apnea, primary aldosteronism, and chronic kidney2 International Journal of Hypertension
Table 1: Secondary forms of hypertension (disease categories).
(i) Endocrine disorders
(ii) Renal disease
(iii) Neurological disorders
(iv) Acute stress
(v) Drug-induced hypertension
(vi) Miscellaneous
disease), which are frequently encountered in hypertensive
patients and are, therefore, the most interesting from the
clinical point of view. In addition, this paper will attempt to
provide a rational for the workup and treatment of patients
with resistant hypertension.
2.Prevalenceand Prognosisof
ResistantHypertension
The exact prevalence of resistant hypertension in the general
population remains unknown. Data from small observa-
tional studies show a wide variation (from 5% to 50%)
according to the studied populations [2–10]. Data from
large clinical trials point towards a relatively high prevalence
of resistant hypertension (20–35%). It has to be noted,
however, that atypical drug combinations have been used
in most of these studies as required by study protocols.
Therefore, the evaluation of the prevalence of resistant
hypertension requires a large, prospective, population-based
study, specially designed for this aim.
Similarly, the prognosis of resistant hypertension is
currently unknown [2–10]. Available evidence addressing
the prognosis of resistant hypertension is scarce, since
virtually no longitudinal study has addressed this topic.
Data from small clinical studies point towards an increased
cardiovascular risk in patients with resistant hypertension.
In addition, patients with resistant hypertension frequently
havecomorbiditiesthatare known toincrease cardiovascular
morbidity and mortality, such as chronic kidney disease,
diabetes, and obesity. Moreover, patients with resistant
hypertension have higher rates of target organ damage than
thegeneralhypertensive populationandarethusatincreased
cardiovascular risk.
3.LifestyleFactors
Resistancetoantihypertensivetreatment isaﬀectedbyseveral
lifestyle factors. Excessive dietary salt intake is common
in patients with resistant hypertension and contributes to
treatment resistance by blunting the blood pressure reduc-
tion of most antihypertensive drugs, including diuretics and
inhibitors of the renin-angiotensin axis [2–10].
Obesity can also contribute to treatment resistance
[2–10]. It has been shown that blood-pressure control is
more diﬃcult to be achieved in obese than lean hypertensive
patients. Several lines of evidence indicate a graded positive
correlation between body mass index and blood pressure
levels, while weight loss results in blood pressure reduction.
Table 2: Drugs inducing or exacerbating hypertension.
(i) Nonsteroidal anti-inﬂammatory drugs
(ii) Oral contraceptives
(iii) Sympathomimetics
(iv) Illicit drugs
(v) Glucocorticoids
(vi) Mineralocorticoids
(vii) Cyclosporine, tacrolimus
(iix) Erythropoietin
(ix) Herbal supplements
(x) VEGF inhibitors
Insulin resistance, sympathetic nervous system overactivity,
sodium retention, and activation of the renin-angiotensin
system have been implicated in the pathogenesis of obesity-
induced hypertension.
Alcohol consumption is another important factor [2–
10].Largealcoholconsumption(>3drinksperday)hasbeen
shown to result in blood pressure elevation. In addition,
blood pressure control might be achieved more diﬃcult in
heavy drinkers due to poor adherence in antihypertensive
therapy. The role of physical inactivity in patients with
resistant hypertension has not been adequately studied.
4.Drug-InducedHypertension
A variety of prescription or over the counter medicines as
well as other exogenous substances may induce hypertension
or contribute to treatment resistance. Drug-induced hyper-
tension is among the most common causes of secondary
hypertension and is frequently encountered in everyday
clinical practice. However, despite the frequent occurrence
of drug-induced hypertension, primary care physicians
frequently miss the opportunity to detect and appropriately
manage this iatrogenic form of secondary hypertension.
Therefore, a detailed and meticulous medical history is of
utmost importance in patients with resistant hypertension,
since the identiﬁcation and subsequent withdrawal of the
oﬀending drug may alleviate treatment resistance. However,
withdrawal of the responsible agent is not always possible;
in such cases, dose reduction and/or search for alternate
treatment may substantially improve or even control blood
pressure levels. Another very important aspect relates to the
great variability oftheeﬀectsofadministered drugsonblood
pressure. The administration of oﬀending drugs can result
in excessive blood pressure elevation in some individuals,
while most individuals will experience little or no increases
of blood pressure. This variability represents a rule without
exception. Therefore, it would be very important to identify
predictors of blood pressure elevation, in order to individu-
alize drug treatment. Up to now, however, no such reliable
predictors have been identiﬁed.
A descriptive list of all exogenous agents capable of
inducing or exaggerating hypertension is presented in
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widely used, represent the most common causes of drug-
induced hypertension, and are thus of major clinical impor-
tance: nonsteroidal anti-inﬂammatory drugs (NSAIDs) and
oral contraceptives. In addition, a brief comment regard-
ing speciﬁc antineoplastic agents (anti-VEGF) that have
emerged as inducers of hypertension is presented at the end
of this chapter, since many clinicians are not aware of this
condition.
4.1. NSAIDs-Induced Hypertension. By far, the most com-
mon cause of drug-induced hypertension is the use of
NSAIDs. In 265 patients with resistant hypertension identi-
ﬁedduringaone-year period, treatmentresistance was drug-
related in 36% of the cases, with NSAIDs being responsible
in 88% (personal unpublished data). Osteoarthritis is highly
prevalent in the general population, and its prevalence
would be even greater due to population aging and the
obesity epidemic [11, 12]. Osteoarthritis and hypertension
often coexist, since both conditions are age related. It
has been reported that approximately 50% of patients
with osteoarthritis suﬀer from hypertension [13]. Although
lifestyle modiﬁcation, exercise, and weight loss are con-
sidered as ﬁrst-line therapeutic measures for patients with
osteoarthritis, the vast majority of such patients require the
systematic or intermittent use of either acetaminophen or
NSAIDsfor pain relief.
Data regarding the eﬀects of NSAIDs on blood pressure
continue to accrue. Two large prospective cohort studies in
normotensive women reported higher risks of subsequent
hypertension among NSAIDs users than in women without
regular NSAIDs administration [14, 15]. In the ﬁrst study,
the risk of developing hypertension was increased about
two times in women using acetaminophen or NSAIDs
[14]. Acetaminophen consumption for 1–4 days per month
and NSAIDs consumption for 5–14 days per month was
necessary for the risk to be apparent. In the second
study, women with frequent use of nonnarcotic analgesics
(>22days/month) had statistically signiﬁcant higher risk for
developing hypertension; in particular, the hazard ratios
were 1.20 for acetaminophen, 1.21 for aspirin, and 1.35
for NSAIDs [15]. It has to be noted that although acetam-
inophen is considered to have a better safety proﬁle than
NSAIDs [16, 17], its use was associated with a moderate
increase in the risk for incident hypertension in both males
and females [18, 19]. Another large, case-control study
revealed a 66% increased risk for initiating antihypertensive
drugs in NSAIDs users compared to nonusers [20]. These
detrimental eﬀects of NSAIDs on blood pressure have been
also observed in two older meta-analyses of randomized
trials with NSAIDs [21, 22]. In the ﬁrst meta-analysis, mean
arterial pressure was increased by 3.3mmHg in hypertensive
patients whereas the increase in normotensive subjects was
negligible (1.1mmHg) [21]. In the second meta-analysis,
NSAIDs resulted in a signiﬁcant mean arterial pressure ele-
vation of 5.0mmHg; blood pressure elevation was apparent
in hypertensive patients with controlled blood pressure,
whereas normotensive individuals did not experience such
an eﬀect [22].
On the contrary, data reporting no or little eﬀect of
NSAIDs on blood pressure exist in the literature as well.
In two cross-sectional studies, no association between use
of NSAIDs and hypertension was found [23, 24]. Similar
ﬁndings were observed in two small randomized studies re-
garding the eﬀects of acetaminophen on blood pressure [25,
26], as well as in studies evaluating the eﬀects of aspirin on
blood pressure in hypertensive patients [27, 28]. In addition,
in a large prospective cohort of 8,229 male normotensive
physicians, analgesic use was not associated with increased
risk of developing hypertension (hazard ratio: 1.12; 95%
CI: 0.97–1.31) [29]. The corresponding hazard ratios were
1.08 (95% CI: 0.87–1.34) for acetaminophen, 1.16 (95% CI:
0.92–1.48) for aspirin, and 1.05 (95% CI: 0.89–1.24) for
NSAIDs.
This apparent heterogeneity of available data on the
eﬀects of traditional NSAIDs on blood pressure becomes
evenmorecomplicatedwhenrecentdatawithselectiveCOX-
2 inhibitors are taken in account. In a meta-analysis of
randomized trials, use of COX-2 inhibitors was associated
with a signiﬁcant increase in blood pressure compared
to placebo (3.85/1.06mmHg) and nonselective NSAIDs
(2.83/1.34mmHg) [30]. However, it was shown that a great
part of blood pressure elevation could be attributed to
rofecoxib. Indeed, rofecoxib use is associated with greater
bloodpressureelevationsthancelecoxibinbothhypertensive
and normotensive individuals [31].
The above-mentioned study highlights another impor-
tant aspect: the potential diﬀerences on blood pressure
eﬀects between the various NSAIDs. In a meta-analysis
of randomized trials, conducted mainly in hypertensive
patients, naproxen and indomethacin were associated with
the largest blood pressure elevations, while piroxicam, sulin-
dac, ibuprofen, and aspirin exhibited little if any eﬀect on
blood pressure [21]. On the contrary, a randomized study in
patients with controlled hypertension showed that the blood
pressure was signiﬁcantly higher with ibuprofen than with
lumiracoxib [32]. Moreover, in 34,701 participants at the
MEDAL (Multinational Etoricoxib and Diclofenac Arthritis
Long term) program, patients assigned to etoricoxib discon-
tinued the study due to hypertension more frequently than
patients randomized to diclofenac [33].
Finally, the potential diﬀerences of the eﬀects of NSAIDs
on blood pressure according to the various antihypertensive
agents coadministered are of great clinical importance. In
a study of elderly hypertensives with osteoarthritis, indo-
methacin had no eﬀect on blood pressure in patients tak-
ing calcium antagonists whereas signiﬁcant blood pressure
elevations were detected in patients taking ACE-inhibitors
[34]. On the contrary, celecoxib exerted similar to placebo
eﬀects in patients taking ACE-inhibitors [35]. Another study
among hypertensive patients with osteoarthritis, comparing
the eﬀects of rofecoxib and celecoxib, revealed no differen-
ces on blood pressure between the two drugs in patients
taking diuretics or calciumantagonists, whereas larger blood
pressure elevations were observed with rofecoxib than with
celecoxib in patients taking ACE-inhibitors or beta blockers
[36].4 International Journal of Hypertension
The above presented information clearly indicates that
available data on the eﬀects of NSAIDs on blood pressure
aresometimes contradictoryand intotalfarfromconclusive.
Convincing data coming from carefully designed random-
ized studies are necessary to: (a) detect potential diﬀerences
between the various NSAIDs on blood pressure, (b) clarify
the eﬀects of coadministering each NSAID with each one of
the various antihypertensive drugcategories, and (c)identify
predictors of blood pressure response to NSAIDs use.
Withdrawal of NSAIDs is indicated in patients with
resistant hypertension, exacerbation of prior hypertension,
orincidenthypertension. SubstitutingNSAIDSwithacetam-
inophen can usually solve the problem. Pain relief is more
likely in patients with osteoarthritis and pain of muscular
skeletal origin. However, this is not always possible in every-
day clinical practice, since patients with chronic inﬂamma-
tory arthritic diseases (rheumatoid arthritis) respond better
to anti-inﬂammatory agents. In such cases, hydrocodone,
tramadol, or nerve blocking might be of help, constituting
eﬀective alternatives to NSAIDs. In cases, however, where
NSAIDs are still necessary, the lower eﬀective dose should be
administered, since existing data point towards dose-related
eﬀects of NSAIDs on blood pressure.
NSAIDs aﬀect blood pressure levels via diﬀerent mech-
anisms: activation of the renin-angiotensin-aldosterone sys-
tem, sodium and water retention, induction of vasoconstric-
tion through endothelin-1 and arachidonic acid metabolites,
and mainly inhibition of renal vasodilatory prostaglandins
(E2 and I2)[ 37–43]. These detrimental eﬀects of NSAIDs
may lead to deterioration of renal function and acute
kidney injury, especially in patients of older age, preexisting
hypertension, chronic kidney disease, or diabetes. In such
patients, calcium antagonists seem to be more suitable
than drugs inhibiting the renin-angiotensin system, since
the concomitant administration of NSAIDs and calcium
antagonists is not accompanied by blood pressure elevation
[36, 39]. The development of NSAIDsthat apart from cyclo-
oxygenase inhibition possess nitric oxide promoting prop-
erties might signiﬁcantly ameliorate current situation and
alleviate the eﬀects of NSAIDs on blood pressure. CINODs
(Cyclo-oxygenase Inhibiting Nitric Oxide Donating drugs)
represent a new class of NSAIDs; CINOD molecules consist
of a traditional NSAID and a nitric oxide-donating chemical
groupconnectedby a linker.Naproxcinod is theﬁrst CINOD
in clinical trials with very promising preliminary results
[44–47].
4.2. Oral Contraceptives. Oral contraceptives represent
another class ofdrugs that are widely used and are capable of
inducing hypertension [48, 49]. The larger study evaluating
the eﬀects of oral contraceptives on blood pressure was the
Nurses’ Health Study, in which more than 60,000 normoten-
sive women were prospectively followed for 4 years [50].
Women using oral contraceptives had an 80% higher risk of
developing hypertension compared to women that were not
usingsuchdrugs.However,withdrawal oforalcontraceptives
abolished this increased risk, underlining the need for close
monitoring in women taking oral contraceptives. Another
important aspect of “pill”-induced hypertension regards the
contribution of oral contraceptives in uncontrolled hyper-
tension. A study in hypertensive women revealed that those
taking oral contraceptives had more severe hypertension and
lower blood-pressure control rates than women using other
contraceptive methods [51].
T h et y p eo fo r a lc o n t r a c e p t i v e ss e e m sa l s ot ob eo fc l i n -
ical importance. Combined oral contraceptives (progestin
and estradiol), which were widely used in the past, were
associated with blood pressure elevations more frequently
than progestin-only oral contraceptives. On the contrary,
drospirenone (a fourth generation progestin) reduces blood
pressure when combined with estradiol [52]. Therefore,
current guidelines recommend the use of progestin-only
oralcontraceptivesinwomenwithestablishedcardiovascular
disease, or major cardiovascular risk factors (such as hyper-
tension) [53, 54].
It can, therefore, be summarized that oral contraceptives
may contribute to resistance in hypertensive women, but the
type of oral contraceptive is important. Close monitoring of
women and withdrawal of oral contraceptives may alleviate
the eﬀects on blood pressure.
4.3. Anti-VEGF Agents. Another classof agentsthat emerged
as inducers of hypertension are the antineoplastic drugs
that target the VEGF pathway. A monoclonal antibody
(bevacizumab) binding to the VEGF-A isoform, as well as
small molecules inhibiting the intracellular tyrosine kinase
d o m a i n so fa l lt h r e eV E G Fr e c e p t o r s ,i su s e do ri su n d e r
clinical testing for the treatment of various malignancies
[55–57]. Hypertension was encountered very frequently in
patients receiving treatment with VEGF-inhibitors [58]. In
particular, 20–30% of patients treated with bevacizumab,
and 15–60% of patients treated with VEGF kinase inhibitors
developed hypertension [59]. Three meta-analyses with
drugs inhibiting theVEGF pathwayuncovereda high relative
riskforincidenthypertension with theseagents:7.5(95%CI:
4.2–13.4)with bevacizumab, 6.11 (95% CI: 2.44–15.32)with
sorafenib, and 21.6 (95% CI: 18.7–24.8) with sunitinib [60–
62]. Interestingly enough, the development of hypertension
has been correlated with the eﬃcacy of these drugs [63–65],
suggesting that hypertension could be used as a surrogate
marker of anti-VEGF eﬃcacy. A phase III trial evaluates this
concept in patients with pancreatic cancer receiving anti-
VEGF agents. Clearly, more data are needed to clarify the
blood pressure eﬀects of the various drugs acting on the
VEGF pathway.
Experimental studies have shown that VEGF upregulates
endothelial nitric oxide synthase [66, 67], enhances nitric
oxide production [68], and induces nitric oxide-dependent
vasorelaxation [69]. Moreover, VEGF was shown to result
in enhanced prostacyclin production and release [70, 71].
It can be therefore anticipated that VEGF inhibition may
lead to reduction of nitric oxide and prostacyclin bioavail-
ability, a subsequent increase of systemic vascular resistance,
and ﬁnally blood pressure elevation. In addition, arteriolar
rarefaction has been observed in animals treated with
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mechanism of hypertension with these drugs [72–74]; pre-
liminary studies in humans reported similar ﬁndings [75,
76]. Finally, enhanced arterial stiﬀness has been suggested as
another contributing factor in the development of hyperten-
sion [77].
The recognition of the pathogenetic mechanisms that
contribute to blood pressure elevation with VEGF-inhibitors
might be helpful in identifying the most appropriate drugs
for the management of these patients. Reliable data evalu-
ating the eﬃcacy of the various antihypertensive drug cate-
gories in anti-VEGF-induced hypertension are missing. Pre-
liminary reports point towards restricted eﬃcacy of diuretics
[78] and beneﬁcial eﬀects of calcium antagonists [79]; how-
ever,appropriate prospective studies are needed in this topic.
5.ObstructiveSleepApnea
A vast amount of evidence demonstrates an association
between obstructive sleep apnea (OSA) and hypertension.
Such an association has been shown in epidemiological,
longitudinal, and cross-sectional studies, as well as in studies
from specialized clinics [80–83]. In addition, it has been
shown that OSA in normotensive subjects predicts future
development of hypertension.
Sympathetic nervous system activation plays a crucial
role in the pathogenesis of hypertension in patients with
OSA. Enhanced upper airway resistance and intermittent
hypoxia are considered to stimulate the sympathetic system,
while the subsequent sympathetic overactivity may result in
blood pressure elevation via vasoconstriction and increased
systemic vascular resistance, increased cardiac output, and
enhanced ﬂuid retention. Aldosterone seems to be the other
signiﬁcant player in this ﬁeld. Increased aldosterone levels
have been observed in OSA patients with resistant hyperten-
sion. The exact nature of the association between OSA and
aldosterone excess remains to be elucidated. Whether OSA
resultsinaldosteroneexcessoraldosteroneexcesscontributes
to OSA, or another underlying factor (like obesity) promot-
ing both aldosterone excess and OSA has not been clariﬁed.
Several studies have reported an extremely high preva-
lence of OSA in patients with resistant hypertension. Two
decades ago, a Swedish study of 16 patients with resistant
hypertension reported a 56% prevalence of OSA in these
patients compared to 19% in patients with controlled hyper-
tension [84]. In a study of 41 consecutive resistant hyper-
tensives, an 83% prevalence of unsuspected OSA was found;
OSAwasdeﬁnedasan apnea/hypopneaindex (AHI)ofmore
than 10 events per hour [85]. Another study of 71 patients
with resistant hypertension revealed an 85% prevalence of
OSA (AHI ≥ 5events/h) [86]. A study from Spain in 62
resistant hypertensives reported a 90% prevalence of OSA
(AHI ≥ 5events/h)[87]. However, when the diagnosis of
OSA was based on 30 or more episodes of apnea/hypopnea
per hour, the prevalence was reduced to 70%, underlining
the importance of accurate and homogeneous deﬁnition of
OSA. Moreover, all the above-mentioned recent studies did
not have a control group in order to exclude the potential
eﬀects of confounding factors. A recent study from Brazil
evaluated 63 patients with resistant hypertension and an
equal number of patients with controlled hypertension,
matched for baseline parameters apart from blood pressure
[88]. A strong and independent association between OSA
and resistant hypertension has been described (odds ratio:
4.8; 95% CI: 2.0–11.7); OSA (AHI ≥ 10events/h) in 71% of
resistant hypertensives and in 38% of responders.
Continuous positive airway pressure (CPAP) represents
the treatment of choice for patients with OSA. It has been
shown that CPAP decreases the incidence of cardiovascular
events in patients with OSA [89, 90].The acute application
of CPAP attenuates blood pressure elevations during sleep
[91]. However, the long-term eﬀects of CPAP on blood pres-
sure are controversial, from studies reporting a signiﬁcant
decrease in blood pressure to studies reporting small or no
eﬀects[92–106].Three meta-analyses havetried toovercome
these discrepancies and revealed that the beneﬁcial eﬀect is
modest, with reductions in systolic blood pressure ranging
from 1.38mmHg to 2.46mmHg [107–109]. It is, therefore,
not surprising that in a recent randomized study, valsartan
was more eﬀective than CPAP in hypertensive patients with
OSA [110].
I th a st ob en o t e d ,h o w e v e r ,t h a tm o s to ft h ea b o v e -
mentioned studies have not been performed exclusively in
hypertensive patients, usually evaluating both normotensive
and hypertensive subjects. In addition, larger blood pressure
reductions were observed in OSA patients with higher
baseline blood pressure levels [107, 111], as expected with
any antihypertensive approach; the motto “the higher the
blood pressure, the larger the reduction” has been veriﬁed
overtheyears.Indeed,twosmallstudiesinOSApatientswith
resistant hypertension revealed signiﬁcant blood pressure
reductions (over 10mmHg) [112, 113]. On the contrary, a
study in 42 patients with resistant hypertension showed a
smaller mean arterial pressure reduction (5.6mmHg; 95%
CI: 2.0–8.7mmHg; P<. 03) [114]. Interestingly enough,
the beneﬁts of CPAP were evident only at 1-year after CPAP
application, suggesting that longer followup periods might
be necessary for the beneﬁts of CPAP treatment to become
apparent in OSA patients with resistant hypertension.
Another important factor is that CPAP treatment allowed
de-escalation of antihypertensive treatment in the majority
of participating patients (71%) [114]. A recent study in
96 patients with OSA and resistant hypertension showed a
slight decrease in systolic blood pressure (1.3mmHg) [115].
However, the reduction was signiﬁcantly larger in patients
with ABPM-conﬁrmed resistant hypertension (7.6mmHg).
In addition, the reduction was even larger in CPAP users
for more than 5.8 hours per day. The above-mentioned data
delineatethecomplexityinidentifyingpatientswith resistant
hypertension andOSAthatwill havethegreaterbeneﬁtswith
CPAP treatment.
An important issue challenging the eﬃcacy of CPAP
relates to patient adherence. Among patients prescribed
CPAP therapy up to 50% failed to initiate it or did not use it
at 3 years [116, 117]. Moreover, among CPAP users, 29–83%
used it for less than 4 hours [118].
Another important aspect of treatment is the choice of
antihypertensive drugsinpatientswith OSA.Thecrucialrole6 International Journal of Hypertension
of SNS activation and the increased levels of aldosterone in
patients with OSA, point towards potential advantages of
drugs inhibiting these pathways on reducing blood pressure.
Indeed, beta blockers were found to be more eﬀective
than other antihypertensive drugs in OSA patients [119];
however, relevant data is still far from conclusive. Even more
interestingly, however, spironolactone was shown not only to
signiﬁcantly lower blood pressure in 12 patients with OSA
and resistant hypertension, butto reduce the severity ofOSA
as well [120]. Further, larger studies are needed, however, to
conﬁrm these beneﬁcial eﬀects of spironolactone in patients
with OSA.
6.PrimaryAldosteronism
Primary aldosteronism (PA) was initially described by Conn
in 1955 [121]. PA is characterized by autonomous produc-
tion of aldosterone by adrenal glands and the subsequent
decrease in renin levels though negative feedback. Aldos-
terone excess leads to hypertension, metabolic alkalosis,
hypernatremia, and potassiumloss resulting inhypokalemia;
the latter is currently considered a late manifestation of PA.
PAcanresultfromanaldosteroneproducingadenoma,bilat-
eral adrenal hyperplasia, glucocorticoid-remediable aldos-
teronism, orrare familial syndromes. Althoughthediagnosis
of adrenal adenomas prevailed during the older times, recent
reports reveal that hyperplasia is more frequent than adrenal
adenomas.
The prevalence of PA in the general hypertensive popu-
lation remains an unresolved issue [122, 123]. Historically,
PA has been considered a rare disease, aﬀecting about 1%
of hypertensive patients [124–127]. However, several studies
performedinthelastdecadereportamuchhigherprevalence
of PA (>10%), suggesting an “epidemic” of this condition
[128–133]. These studies, however, were carried out in
specialized referral centers, raising concerns of selection
bias. Indeed, a study of more than 600 unselected patients
with hypertension conducted in Chile, revealed a 6.1%
prevalence of PA [134], suggesting that the true prevalence
is somewhere in the middle. However, irrespective of its
exact prevalence, PA has become fashionable again, with
leading specialized centersappearing all overtheworld, from
Alabama (D. Calhoun) to Italy (G. Rossi) and from Australia
(M. Stowasser) to United Kingdom (M. Brown).
The prevalence of hypertension relates to the severity
of hypertension. In the study from Chile, PA was found in
1.99% of patients with Stage I hypertension and in 13.2%
of patients with stage III hypertension [134]. In another
study of more than 400 Czech patients with moderate-
to-severe hypertension, the prevalence of PA was even
higher (19%) [135]. Data from clinical practice indicates
that resistant hypertension represents the condition with
the highest probability of detecting PA [136, 137]. Indeed,
the prevalence of PA ranged from 14–23% in 5 studies
conducted in resistant hypertensives [138–142]. A study of
88 patients with resistant hypertension in Alabama showed
that 18 patients (20%) suﬀered from PA; PA prevalence was
race independent [138]. The prevalence of PA was quite
Table 3: Endocrine causes of secondary hypertension.
(i) Primary aldosteronism
(ii) Pheochromocytoma
(iii) Hyperthyroidism
(iv) Hypothyroidism
(v) Cushing’s syndrome
(vi) Acromegaly
(vii) Hyperparathyroidism
(iix) Carcinoid tumor
(ix) Congenital adrenal hyperplasia
similar in two other studies, one from Seattle (17%) and
one from Norway (23%) [139, 140]. A somehow lower
prevalence was found in the remaining two studies. A
study from Spain reported a 14% prevalence of primary
hyperaldosteronisminpatientswithrefractory hypertension;
however, patients with hypokalemia were excluded from
the study suggesting that the true prevalence of primary
aldosteronism could be up to two times higher than the one
reported [141]. Finally, a similar prevalence of 14% has been
reported in diabetic subjects with resistant hypertension
[142].
The above-mentioned studies have reported a PA preva-
lence of 14–23% in patients with resistant hypertension,
suggesting that the true prevalence would be around 20%.
However, it has to be recognized that all these studies
included a small number of patients. In total, only 418
patients participated in these studies, underlining the need
for larger studies. A recent study from Greece evaluated
2,032 patients with resistant hypertension, with 1,616 of
them having “true” resistant hypertension [143]. It was
found that about 21% of studied patients had a high
aldosterone to renin ratio combined with high aldosterone
levels, which were suggestive of primary aldosteronism.
However, only half of them (11.3%) were suﬀering for
primary aldosteronism, conﬁrmed by salt suppression tests
and response to spironolactone.
Another very interesting ﬁnding is the coexistence of
PA and OSA in patients with resistant hypertension. In
one study of 109 patients with resistant hypertension, OSA
was found in 84% of patients with PA [144]. However, in
another study, PA was found in only 34% of patients with
OSA [145]. The pathophysiologic mechanisms underlining
the co-occurrence of these conditions need further elucida-
tion.
The other forms of endocrine hypertension, presented
in Table 3, are less frequently encountered in hypertensive
patients and, therefore, represent rare causes of resistant
hypertension. In addition, the clinical presentation of these
endocrine forms of secondary hypertension is usually so
characteristic that is really hard to be missed. Since this
paper addresses the most common secondary causes of
resistant hypertension, readers interested in endocrine hy-
pertension may refer to other recently published reviews
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7.ChronicKidneyDisease
Hypertension is commonly found in patients with chronic
kidney disease (CKD), with 75% of CKD patients taking
antihypertensive drugs [148]. On the other hand, renal
disease represents one of the forms of target organ damage
inducedby hypertension [149].Itseems that therelationship
between hypertension and CKD is bidirectional; the kidney
is both “the victim and the culprit” in this relationship.
All recent guidelines recommend lower blood pressure
goals in patients with CKD, especially when frank albumin-
uria is present [149–151]. It has been shown, however, that
thevastmajority (>85%)ofpatientswith CKDfailtoachieve
these goals; blood pressure control rates in CKD patients
are lower than in other hypertensive patients despite the
use of 3 antihypertensive drugs in average [152, 153]. It
is, therefore, not surprising that the prevalence of resistant
hypertension in patients with CKD is over 50% [154].
However, CKD is usually underappreciated as a cause of
resistant hypertension, mainly because these patients are
being followed at specialized nephrology clinics.
Several factors contribute to treatment resistance in
patients with CKD. Sodium and ﬂuid retention plays a
cardinal role, while the increased activity of both the
sympathetic and the renin-angiotensin-aldosterone systems
greatly contribute to treatment resistance. Moreover, vascu-
lar alterations both at a structural and functional (increased
endothelin-1, decreased nitric oxide bioavailability) level,
combined with the consequences of renal ischemia play an
additional role [155].
Another signiﬁcant contributor to treatment resistance
in patients with CKD regards the use of diuretics in these
patients. It has been observed that restrictions in diuretic use
were the primary cause of resistant hypertension in patients
with CKD [156]. Restricted diuretic use includes either
lower doses or inappropriate drug selection; thiazides are
usually not eﬀective when GFR is lower than 40 and should,
therefore, be replaced by loop diuretics in such patients. In
t h ec a s et h a tf u r o s e m i d ei sc h o s e n ,i th a st ob eg i v e na tl e a s t
twice daily due to its limited half-life. Finally, dietary salt
reduction may eﬀectively attenuate volume expansion and
oﬀer signiﬁcant beneﬁts in these patients.
Another important key aspect in patients with CKD is
the assessment of urinary albumin excretion. Microalbu-
minuria and especially macroalbuminuria are related with
marked increments in cardiovascular risk. Drugs inhibiting
the rennin-angiotensin axis (ACE-inhibitors, angiotensin
receptor blockers, and direct rennin inhibitors) should
be included in the therapeutic regime, since their use is
associated with reduction of albuminuria and end-stage
renal disease [157]. The combination of ACE-inhibitors with
angiotensin receptor blockers has not proven any beneﬁts in
high-risk patients at the ONTARGET study and was even
associated with more adverse eﬀects [158, 159]. However,
this combination might still be beneﬁcial in patients with
CKD and overt albuminuria [160].
Renovascular hypertension is another common form of
secondary hypertension. Renovascular hypertension is of
atheroscleroticorigin inthevast majority of cases,thusbeing
more frequent in older individuals, diabetics, smokers, and
in patients with atherosclerotic lesions at other vascular beds
[161,162].Indeed,about25%ofpatientsundergoingcardiac
catheterization are found to have renal artery stenosis (RAS)
higher than 70%, which could be of clinical signiﬁcance
[163, 164]. On the other hand, ﬁbromuscular dysplasia is
a much less frequent cause of RAS (approximately 10%)
than atherosclerosis, and is more frequently encountered in
younger females.
Renovascular hypertension is common among patients
with resistant hypertension. Older studies suggested that 1
out of 3 patients with secondary hypertension has renovas-
cular hypertension [165, 166]. Unfortunately, recent studies
in patients with resistant hypertension usually focus on OSA
and PA and do not even mention RAS. It seems that RAS
came out of fashion, mainly because its diagnosis with non-
invasive methods remains tricky. Although several methods
are used for the detection of RAS (duplex ultrasound, renal
scintigraphy, ands CT and MR angiography) with rather
good sensitivity and speciﬁcity [167], the diagnosis of reno-
vascular hypertension represents an unfulﬁlled challenge for
primary care physicians and remains mainly restrained in
specialized centers.
Another important aspect regards the management of
patients with RAS. Three choices are available nowadays:
surgical treatment, balloon angioplasty (with or without
stenting), and conservative drug treatment. The surgical
approach has subsided during the last decades and is now
reserved for speciﬁc indications. Available data regarding
the remaining two methods are inconclusive. Balloon angio-
plasty was not found superior to optimal drug treatment
in the recently published ASTRAL study; several drawbacks,
however, limit the interpretation of study ﬁndings [168].
Another ongoing trial, the CORAL study, will provide hard-
endpoint data with the two diﬀerent approaches [169].
8.Rationalforthe Managementof
ResistantHypertension
The management of resistant hypertension represents a
challenge for the astute clinician. Although it seems rational
for patients with resistant hypertension to be referred to
specialized hypertension clinics, the initial evaluation can be
performed by primary care physicians. We will, therefore,
attempttoprovideastep-by-stepapproachfortheevaluation
and treatment of patients with resistant hypertension. The
ﬁrst steps may take place at the primary care level, in the
attempt to substantially reduce the number of referred pa-
tients and prevent unnecessary costs and patient discomfort.
In summary, the following steps need to be followed in
the management of resistant hypertension.
(i) Veriﬁcation of “true” Resistant Hypertension. Patients
with “pseudoresistance” should be identiﬁed and excluded
from further evaluation. Three main problems require
special attention at this step: patient-related problems,
physician-related problems, and blood-pressure technique-
related problems.8 International Journal of Hypertension
(a) Patient-Related Problems. Adherence to antihyper-
tensive treatment is of utmost importance for the
eﬀective management of arterial hypertension. Both
epidemiological and clinical data strongly indicate
that patient adherence to antihypertensive therapy is
poor [170–175]. Almost half of treated hypertensive
patients discontinue drug administration during the
ﬁrst year of treatment whereas long-term adherence
rates are even lower. In addition, small studies in
patients with resistant hypertension suggest that
poor patient adherence represents one of the most
common causes of treatment resistance [176, 177].
Detailed medical history, information by relatives,
and use of speciﬁc questionnaires might helpin iden-
tifying patients with poor adherence; these methods
can be easily applied by primary care physicians with
obvious beneﬁts. The pursuit of improved patient
adherence attracts great scientiﬁc interest. Modern
technology is used with good results (electronic
pill boxes, internet monitoring) but is not widely
applied yet. Special programmes using close contact
of health care professionals (doctors, nurses, and
pharmacists) with patients seem also eﬀective but
lackwideapplicationaswell.Finally,simpliﬁcationof
dosing schedule and use ofdrugs with superior safety
proﬁle may be of beneﬁt.
(b) Physician-Related Problems.P h y s i c i a ni n e r t i ai sa n -
other important factor contributing in treatment
resistance. It has been shown that doctors are fre-
quentlyreluctantto maximize drugtherapy, eitherby
adding antihypertensive drugs or by switching drug
category, in order to achieve blood pressure goals
[178–181]. Indeed, a gap between guideline recom-
mendations and their implementation in everyday
clinical practice has been recognized and represents
a signiﬁcant obstacle in achieving satisfying blood
pressure control rates [149, 150]. Another contribu-
tor to treatment resistance is the use of inappropriate
drug combinations or suboptimal doses of antihy-
pertensive drugs. Indeed, a study of patients with
resistant hypertension revealed that simple measures,
such as increasing diuretic dosing or switching to
appropriate diuretics, can result in significant blood
pressure reductions [156].
In our opinion, however, the most important line
of evidence suggesting physician inertia on treat-
ment resistance, comes from recent studies reporting
signiﬁcantly higher control rates of hypertension
[182–185]. In these studies, various measures have
been used to motivate physicians in achieving blood
pressure goals, resulting in improved control rates.
Therefore, physicians need to be the focus of future
eﬀorts for the eﬀective management of resistant
hypertension.
(c) Blood Pressure Technique-Related Problems.T h er e -
quirements for proper blood pressure measurement
have been standardized [186] and incorporated in
the guidelines for the management of arterial hyper-
tension [149, 150]. However, the measurement of
oﬃce blood pressure in clinical practice frequently
deviates from the recommendations. Therefore,
falsely elevated blood pressure levelsmay be recorded
due to several reasons: inappropriate cuﬀ size, failure
to comply with the recommendations regarding
suﬃcient time before blood-pressure measurement,
arm support at the heart level, assessment in a
quietroom, triplicate recordings, and coﬀeeintakeor
smoking before blood pressure measurement [187–
189].The abovementioned factors may contributeto
overestimation of blood pressure and “pseudoresis-
tance”. Similarly, false elevations may be encountered
in older patients, in whom adequate artery compres-
sion may not be achieved due to marked arterial
calciﬁcation.Therefore, it isessential toassure proper
techniques of blood pressure measurement in order
to limit the rates of pseudoresistance.
Another important aspect of “resistance” is recog-
nition of “white coat” hypertension. It has been
noted that in 20–30% of patients with resistant
hypertension, treatment resistance may be attributed
to the “white coat” eﬀect [143, 190–192]. Target
organ damage is less frequent in these patients,
who actually do not suﬀer from “true” resistant hy-
pertension. Therefore, either ambulatory or home
blood-pressure monitoring should be performed in
every patient with resistant hypertension, in order to
excludethe“white coat” eﬀectand avoidunnecessary
referrals.
(ii) Exclusion of Drug-Induced Hypertension. As discussed in
the ﬁrst sectionofthispaper, severaldrugsmay induceblood
pressure elevations, with NSAIDs and oral contraceptives
being the most common. Therefore, practicing physicians
need to be very meticulous during medical history taking, in
ordertouncovertheuseofdrugsinducinghypertension.The
withdrawal of oﬀended drugs usually results to the return
of blood pressure at previous levels. In the case, however,
that the drug is considered essential for the treatment
of comorbidities, the substitution to another drug with a
more friendly proﬁle or the reduction of dose might be
beneﬁcial.
(iii) Reduction of Dietary Sodium Intake. Sodium intake is
excessive in the Western world, mainly due to the “hidden
salt” in processed foods. The average sodium intake is far
higher than the recommended 2.4 grams per day, reaching
even 10g/day in patients with resistant hypertension [193].
Plasma volume expansion represents one of the cardinal
characteristics of resistant hypertension. The important role
of sodium restriction in patients with resistant hypertension
is highlighted by the ﬁndings of a recent study. It was
found that reductions in sodium intake are accompanied by
signiﬁcant reductions in blood pressure levels in resistant
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(iv) Evaluation for Secondary Causes of Hypertension. As
previouslydiscussed, obstructivesleep apnea,primary aldos-
teronism, and chronic kidney disease represent the most
common secondary causes of resistant hypertension whereas
several other conditions may be responsible for treatment
resistance as well. The diagnostic workup for secondary
hypertension is demanding, requires special knowledge and
technology, and should be performed in specialized referral
centers, which are familiar with secondary hypertension.
Although a detailed description of the diagnostic workup is
beyond the scope of this paper, some signs and/or ﬁndings
raising the suspicion of secondary hypertension need to
be mentioned. In particular: obesity, snoring, daytime
sleepiness, and increased neck diameter raise the suspicion
of obstructive sleep apnea; hypokalemia (either spontaneous
or diuretic induced) is present in about half of cases with
primary aldosteronism; active urinesediment, small kidneys,
and impaired renal function point towards chronic kidney
disease; abdominal bruit, diﬀerence in renal size raise the
suspicion of renal artery stenosis..
(v) Pharmacologic Management of Resistant Hypertension.
The pathophysiology of resistant hypertension provides the
rational for the eﬀective management of this clinical entity.
The combination of increased systemic vascular resistance
with marked volume expansion in many cases, renders
the triple combination of a drug inhibiting the renin-
angiotensin axis (ACE-inhibitors or angiotensin receptor
blockers) with a calcium antagonist and a diuretic a very
attractive combination for the majority of patients (unless
these drugs are contraindicated or not tolerated, or other
drugs are indicated due to comorbidities). However, reliable
data verifying the superiority of this combination over other
combinations is not available. Special attention has to be
drawn in maximizing the dose of diuretics or switching to
loop diuretics in patients with low GFR. The overactivation
of the sympathetic nervous system renders beta blockers,
alpha blockers, and centrally acting antihypertensive drugs
(clonidine, alpha methyldopa) of potential beneﬁt in many
patientswhen addedinprevioustherapy.Directvasodilators,
such as hydralazine and minoxidil, can be very eﬀective for
bloodpressure management,especiallyinAfrican Americans
and patients with chronic kidney disease. A vast amount of
evidence indicates that spironolactone is a drug of choice
in the treatment of resistant hypertension. Several studies
revealed impressive blood pressure reductions in patients
with resistant hypertension when spironolactone was added
in the therapeutic regime [195–205]. Chronotherapy rep-
resents an important approach for the management of
resistant hypertension. Administration of one antihyperten-
sive drug at bedtime has been shown to improve blood
pressure control in patients with resistant hypertension
[206–208].
(vi) Newer Drugs for the Management of Resistant Hyperten-
sion . Endothelin antagonists exhibited promising results in
preliminary studies [209]. The future of darusentan remains
unclear, however, since in another study in patients with
resistant hypertension, darusentan failed to be more eﬀective
than placebo regarding oﬃce blood pressure reductions.
It has to be mentioned, however, that in the latter study,
signiﬁcant diﬀerences were detected in ambulatory blood
pressure between darusentan and placebo [210], indicating
that further studies are needed with this drug category.
Another interesting approach for the management of resis-
tant hypertension is the administration of nitric oxide
donors. In a recent small clinical study of six patients with
resistant hypertension, the combination of nitrates with
phosphodiesterase-5 inhibitors resulted in signiﬁcant blood
pressure reduction [211]. However, this ﬁnding has to be
interpreted with caution, since the concomitant use of these
medicationsiscontraindicatedduetothepossibilityofsevere
hypotension.
(vii) Interventional Management of Resistant Hypertension.
Despite the wide application of antihypertensive therapy, a
substantial portion of the hypertensive population remains
uncontrolled although taking more than three drugs. This
situation calls for testing alternative approaches in patients
with resistant hypertension. Carotid baroreceptors and renal
sympathetic overdrive play a signiﬁcant role in blood pres-
sure regulation [212, 213]. During the last decade, two new
approaches have revived the use of interventional techniques
for the management of resistant hypertension. Carotid
baroreceptor stimulation and renal sympathetic denervation
have shown promising preliminary results in patients with
resistant hypertension [214, 215]. However, further studies
are needed to establish their role in the management of
resistant hypertension.
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